BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 2016;22:278-87. [PMID: 26855150 DOI: 10.1038/nm.4038] [Cited by in Crossref: 127] [Cited by in F6Publishing: 105] [Article Influence: 21.2] [Reference Citation Analysis]
Number Citing Articles
1 Hennig A, Wolf L, Jahnke B, Polster H, Seidlitz T, Werner K, Aust DE, Hampe J, Distler M, Weitz J, Stange DE, Welsch T. CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids. Stem Cells Int 2019;2019:1024614. [PMID: 31191661 DOI: 10.1155/2019/1024614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
2 He L, Zhou X, Huang N, Li H, Li T, Yao K, Tian Y, Hu CA, Yin Y. Functions of pregnane X receptor in self-detoxification. Amino Acids 2017;49:1999-2007. [PMID: 28534176 DOI: 10.1007/s00726-017-2435-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
3 Qixing M, Juqing X, Yajing W, Gaochao D, Wenjie X, Run S, Anpeng W, Lin X, Feng J, Jun W. The expression levels of CYP3A4 and CYP3A5 serve as potential prognostic biomarkers in lung adenocarcinoma. Tumour Biol 2017;39:1010428317698340. [PMID: 28381170 DOI: 10.1177/1010428317698340] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
4 Steiger K, Schlitter AM, Weichert W, Esposito I, Wester HJ, Notni J. Perspective of αvβ6-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions. Mol Imaging 2017;16:1536012117709384. [PMID: 28627323 DOI: 10.1177/1536012117709384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
5 Abel EV, Goto M, Magnuson B, Abraham S, Ramanathan N, Hotaling E, Alaniz AA, Kumar-Sinha C, Dziubinski ML, Urs S, Wang L, Shi J, Waghray M, Ljungman M, Crawford HC, Simeone DM. HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. Elife 2018;7:e33947. [PMID: 30074477 DOI: 10.7554/eLife.33947] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
6 Teles Alves I, Cohen N, Ersan PG, Eyre R, Godet I, Holovanchuk D, Jackstadt R, Kyjacova L, Mahal K, Noguera-Castells A, Recalde-Percaz L, Sleeman JP. EACR-MRS conference on Seed and Soil: In Vivo Models of Metastasis. Clin Exp Metastasis 2017;34:449-56. [PMID: 29589151 DOI: 10.1007/s10585-018-9886-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Raffenne J, Cros J. [Molecular characterisation defines several subtypes of pancreatic ductal adenocarcinoma]. Bull Cancer 2018;105:55-62. [PMID: 29273547 DOI: 10.1016/j.bulcan.2017.11.010] [Reference Citation Analysis]
8 Dumbovic G, Biayna J, Font B, Buschbeck M, Forcales SV. Barcelona conference on epigenetics and cancer 2016 - beyond cancer genomes. Epigenetics 2017;12:238-45. [PMID: 28121228 DOI: 10.1080/15592294.2017.1281503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Kruger SF, Lohneis A, Abendroth A, Berger AW, Ettrich TJ, Waidmann O, Kapp M, Steiner B, Kumbrink J, Reischer A, Haas M, Westphalen CB, Zhang D, Miller-Phillips L, Burger PJ, Kobold S, Werner J, Subklewe M, von Bergwelt-Baildon M, Kunzmann V, Seufferlein T, Siveke JT, Sinn M, Heinemann V, Ormanns S, Boeck S. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study. ESMO Open 2022;7:100388. [PMID: 35121522 DOI: 10.1016/j.esmoop.2022.100388] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Muzumdar MD, Chen PY, Dorans KJ, Chung KM, Bhutkar A, Hong E, Noll EM, Sprick MR, Trumpp A, Jacks T. Survival of pancreatic cancer cells lacking KRAS function. Nat Commun 2017;8:1090. [PMID: 29061961 DOI: 10.1038/s41467-017-00942-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 14.0] [Reference Citation Analysis]
11 Haas M, Siveke JT, Schenk M, Lerch MM, Caca K, Freiberg-Richter J, Fischer von Weikersthal L, Kullmann F, Reinacher-Schick A, Fuchs M, Kanzler S, Kunzmann V, Ettrich TJ, Kruger S, Westphalen CB, Held S, Heinemann V, Boeck S. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'. Eur J Cancer 2018;94:95-103. [PMID: 29549862 DOI: 10.1016/j.ejca.2018.02.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
12 Chia S, Low JL, Zhang X, Kwang XL, Chong FT, Sharma A, Bertrand D, Toh SY, Leong HS, Thangavelu MT, Hwang JSG, Lim KH, Skanthakumar T, Tan HK, Su Y, Hui Choo S, Hentze H, Tan IBH, Lezhava A, Tan P, Tan DSW, Periyasamy G, Koh JLY, Gopalakrishna Iyer N, DasGupta R. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun 2017;8:435. [PMID: 28874669 DOI: 10.1038/s41467-017-00451-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
13 Bispo S, Farias TDJ, de Araujo-Souza PS, Cintra R, Dos Santos HG, Jorge NAN, Castro MAA, Wajnberg G, Scherer NM, Genta MLND, Carvalho JP, Villa LL, Sichero L, Passetti F. Dysregulation of Transcription Factor Networks Unveils Different Pathways in Human Papillomavirus 16-Positive Squamous Cell Carcinoma and Adenocarcinoma of the Uterine Cervix. Front Oncol 2021;11:626187. [PMID: 34094909 DOI: 10.3389/fonc.2021.626187] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Tan DJ, Mitra M, Chiu AM, Coller HA. Intron retention is a robust marker of intertumoral heterogeneity in pancreatic ductal adenocarcinoma. NPJ Genom Med 2020;5:55. [PMID: 33311498 DOI: 10.1038/s41525-020-00159-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Lorentzen A, Becker PF, Kosla J, Saini M, Weidele K, Ronchi P, Klein C, Wolf MJ, Geist F, Seubert B, Ringelhan M, Mihic-Probst D, Esser K, Roblek M, Kuehne F, Bianco G, O'Connor T, Müller Q, Schuck K, Lange S, Hartmann D, Spaich S, Groß O, Utikal J, Haferkamp S, Sprick MR, Damle-Vartak A, Hapfelmeier A, Hüser N, Protzer U, Trumpp A, Saur D, Vartak N, Klein CA, Polzer B, Borsig L, Heikenwalder M. Single cell polarity in liquid phase facilitates tumour metastasis. Nat Commun 2018;9:887. [PMID: 29491397 DOI: 10.1038/s41467-018-03139-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
16 Oldfield LE, Connor AA, Gallinger S. Molecular Events in the Natural History of Pancreatic Cancer. Trends Cancer 2017;3:336-46. [PMID: 28718411 DOI: 10.1016/j.trecan.2017.04.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
17 Pan H, Yang L, Bai H, Luo J, Deng Y. Ginsenoside Rg3 increases gemcitabine sensitivity of pancreatic adenocarcinoma via reducing ZFP91 mediated TSPYL2 destabilization. Journal of Ginseng Research 2021. [DOI: 10.1016/j.jgr.2021.08.004] [Reference Citation Analysis]
18 Bian B, Juiz NA, Gayet O, Bigonnet M, Brandone N, Roques J, Cros J, Wang N, Dusetti N, Iovanna J. Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi). Front Oncol 2019;9:475. [PMID: 31231611 DOI: 10.3389/fonc.2019.00475] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
19 Park E, Yoo JE, Hwang HK, Kang CM, Lee CK, Kim MH, Bang S, Park YN. Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2021. [PMID: 34318617 DOI: 10.1002/jhbp.1025] [Reference Citation Analysis]
20 Brunetti O, Luchini C, Argentiero A, Tommasi S, Mangia A, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Santini D, Doglioni C, Maiello E, Lawlor RT, Mazzaferro V, Lonardi S, Giuliante F, Brandi G, Scarpa A, Cascinu S, Silvestris N. The Italian Rare Pancreatic Exocrine Cancer Initiative. Tumori 2019;105:353-8. [PMID: 30967031 DOI: 10.1177/0300891619839461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chai SC, Wright WC, Chen T. Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer. Med Res Rev 2020;40:1061-83. [PMID: 31782213 DOI: 10.1002/med.21648] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
22 Oladimeji PO, Wright WC, Wu J, Chen T. RNA interference screen identifies NAA10 as a regulator of PXR transcription. Biochem Pharmacol 2019;160:92-109. [PMID: 30566892 DOI: 10.1016/j.bcp.2018.12.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
23 Kawahara B, Faull KF, Janzen C, Mascharak PK. Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel. J Med Chem 2021;64:8437-46. [PMID: 34097831 DOI: 10.1021/acs.jmedchem.1c00404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Camolotto SA, Belova VK, Snyder EL. The role of lineage specifiers in pancreatic ductal adenocarcinoma. J Gastrointest Oncol 2018;9:1005-13. [PMID: 30603119 DOI: 10.21037/jgo.2018.05.04] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Kafita D, Nkhoma P, Zulu M, Sinkala M. Proteogenomic analysis of pancreatic cancer subtypes. PLoS One 2021;16:e0257084. [PMID: 34506537 DOI: 10.1371/journal.pone.0257084] [Reference Citation Analysis]
26 Schneider G, Wirth M, Keller U, Saur D. Rationale for MYC imaging and targeting in pancreatic cancer. EJNMMI Res 2021;11:104. [PMID: 34637026 DOI: 10.1186/s13550-021-00843-1] [Reference Citation Analysis]
27 Le Large TYS, Bijlsma MF, Kazemier G, van Laarhoven HWM, Giovannetti E, Jimenez CR. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Semin Cancer Biol. 2017;44:153-169. [PMID: 28366542 DOI: 10.1016/j.semcancer.2017.03.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
28 Tu M, Klein L, Espinet E, Georgomanolis T, Wegwitz F, Li X, Urbach L, Danieli-Mackay A, Küffer S, Bojarczuk K, Mizi A, Günesdogan U, Chapuy B, Gu Z, Neesse A, Kishore U, Ströbel P, Hessmann E, Hahn SA, Trumpp A, Papantonis A, Ellenrieder V, Singh SK. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Nat Cancer 2021;2:1185-203. [PMID: 35122059 DOI: 10.1038/s43018-021-00258-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Gengenbacher N, Singhal M, Augustin HG. Preclinical mouse solid tumour models: status quo, challenges and perspectives. Nat Rev Cancer 2017;17:751-65. [PMID: 29077691 DOI: 10.1038/nrc.2017.92] [Cited by in Crossref: 125] [Cited by in F6Publishing: 110] [Article Influence: 25.0] [Reference Citation Analysis]
30 Dreyer SB, Jamieson NB, Upstill-Goddard R, Bailey PJ, McKay CJ, Biankin AV, Chang DK; Australian Pancreatic Cancer Genome Initiative. Defining the molecular pathology of pancreatic body and tail adenocarcinoma. Br J Surg 2018;105:e183-91. [PMID: 29341146 DOI: 10.1002/bjs.10772] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
31 Torres C, Grippo PJ. Pancreatic cancer subtypes: a roadmap for precision medicine. Ann Med 2018;50:277-87. [PMID: 29537309 DOI: 10.1080/07853890.2018.1453168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
32 Adam RS, Blomberg I, Ten Hoorn S, Bijlsma MF, Vermeulen L. The recurring features of molecular subtypes in distinct gastrointestinal malignancies-A systematic review. Crit Rev Oncol Hematol 2021;164:103428. [PMID: 34284100 DOI: 10.1016/j.critrevonc.2021.103428] [Reference Citation Analysis]
33 Thomas H. CYP3A5 contributes to PDAC chemoresistance. Nat Rev Gastroenterol Hepatol 2016;13:188-188. [DOI: 10.1038/nrgastro.2016.36] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
34 Martens S, Lefesvre P, Nicolle R, Biankin A, Puleo F, Van Laethem J, Rooman I. Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. Annals of Oncology 2019;30:1428-36. [DOI: 10.1093/annonc/mdz181] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 7.7] [Reference Citation Analysis]
35 Jabs J, Zickgraf FM, Park J, Wagner S, Jiang X, Jechow K, Kleinheinz K, Toprak UH, Schneider MA, Meister M, Spaich S, Sütterlin M, Schlesner M, Trumpp A, Sprick M, Eils R, Conrad C. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations. Mol Syst Biol 2017;13:955. [PMID: 29180611 DOI: 10.15252/msb.20177697] [Cited by in Crossref: 91] [Cited by in F6Publishing: 83] [Article Influence: 18.2] [Reference Citation Analysis]
36 Law HC, Lagundžin D, Clement EJ, Qiao F, Wagner ZS, Krieger KL, Costanzo-Garvey D, Caffrey TC, Grem JL, DiMaio DJ, Grandgenett PM, Cook LM, Fisher KW, Yu F, Hollingsworth MA, Woods NT. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response. Clin Cancer Res 2020;26:1065-76. [PMID: 31848187 DOI: 10.1158/1078-0432.CCR-19-1496] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
37 Wright WC, Chenge J, Chen T. Structural Perspectives of the CYP3A Family and Their Small Molecule Modulators in Drug Metabolism. Liver Res 2019;3:132-42. [PMID: 32789028 DOI: 10.1016/j.livres.2019.08.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
38 Abe S, Kobayashi K, Oji A, Sakuma T, Kazuki K, Takehara S, Nakamura K, Okada A, Tsukazaki Y, Senda N, Honma K, Yamamoto T, Ikawa M, Chiba K, Oshimura M, Kazuki Y. Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology. Sci Rep 2017;7:15189. [PMID: 29123154 DOI: 10.1038/s41598-017-15033-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
39 Yao W, Maitra A, Ying H. Recent insights into the biology of pancreatic cancer. EBioMedicine. 2020;53:102655. [PMID: 32139179 DOI: 10.1016/j.ebiom.2020.102655] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
40 Oria VO, Bronsert P, Thomsen AR, Föll MC, Zamboglou C, Hannibal L, Behringer S, Biniossek ML, Schreiber C, Grosu AL, Bolm L, Rades D, Keck T, Werner M, Wellner UF, Schilling O. Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance. Transl Oncol 2018;11:1307-22. [PMID: 30172883 DOI: 10.1016/j.tranon.2018.08.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
41 Nadler WM, Waidelich D, Kerner A, Hanke S, Berg R, Trumpp A, Rösli C. MALDI versus ESI: The Impact of the Ion Source on Peptide Identification. J Proteome Res 2017;16:1207-15. [PMID: 28176526 DOI: 10.1021/acs.jproteome.6b00805] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
42 Lee HS, Kim E, Lee J, Park SJ, Hwang HK, Park CH, Jo SY, Kang CM, Hong SM, Kang H, Jo JH, Cho IR, Chung MJ, Park JY, Park SW, Song SY, Han JM, Kim S, Bang S. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. EBioMedicine 2021;65:103218. [PMID: 33639403 DOI: 10.1016/j.ebiom.2021.103218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
43 Lolodi O, Wang YM, Wright WC, Chen T. Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery. Curr Drug Metab 2017;18:1095-105. [PMID: 28558634 DOI: 10.2174/1389200218666170531112038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
44 Matheux A, Gassiot M, Fromont G, Leenhardt F, Boulahtouf A, Fabbrizio E, Marchive C, Garcin A, Agherbi H, Combès E, Evrard A, Houédé N, Balaguer P, Gongora C, Mbatchi LC, Pourquier P. PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1. Cancers (Basel) 2021;13:3635. [PMID: 34298852 DOI: 10.3390/cancers13143635] [Reference Citation Analysis]
45 Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ, Wang ZF, Wu XL, Zhou CH, Yan JY, Hu BY, Kong B, Fu DL, Bruns C, Zhao Y, Qin LX, Dong QZ. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther 2021;6:249. [PMID: 34219130 DOI: 10.1038/s41392-021-00659-4] [Reference Citation Analysis]
46 Du Y, Zhao B, Liu Z, Ren X, Zhao W, Li Z, You L, Zhao Y. Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic. J Cancer 2017;8:513-22. [PMID: 28367231 DOI: 10.7150/jca.17622] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
47 Li B, Jiang J, Assaraf YG, Xiao H, Chen Z, Huang C. Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. Drug Resistance Updates 2020;53:100720. [DOI: 10.1016/j.drup.2020.100720] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
48 Assenat E, Mineur L, Mollevi C, Lopez-Crapez E, Lombard-Bohas C, Samalin E, Portales F, Walter T, de Forges H, Dupuy M, Boissière-Michot F, Ho-Pun-Cheung A, Ychou M, Mazard T. Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). Int J Cancer 2021;148:682-91. [PMID: 33405269 DOI: 10.1002/ijc.33225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Panzeri V, Manni I, Capone A, Naro C, Sacconi A, Di Agostino S, de Latouliere L, Montori A, Pilozzi E, Piaggio G, Capurso G, Sette C. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma. Mol Oncol 2021;15:579-95. [PMID: 33159833 DOI: 10.1002/1878-0261.12847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
50 Gao Y, Zhang E, Fei X, Kong L, Liu P, Tan X. Identification of Novel Metabolism-Associated Subtypes for Pancreatic Cancer to Establish an Eighteen-Gene Risk Prediction Model. Front Cell Dev Biol 2021;9:691161. [PMID: 34447748 DOI: 10.3389/fcell.2021.691161] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Lynch C, Sakamuru S, Huang R, Niebler J, Ferguson SS, Xia M. Characterization of human pregnane X receptor activators identified from a screening of the Tox21 compound library. Biochem Pharmacol 2021;184:114368. [PMID: 33333074 DOI: 10.1016/j.bcp.2020.114368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Buck E, Sprick M, Gaida MM, Grüllich C, Weber TF, Herpel E, Bruckner T, Koschny R. Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer. Oncol Lett 2019;17:3890-8. [PMID: 30881507 DOI: 10.3892/ol.2019.10043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
53 Görgülü K, Diakopoulos KN, Ai J, Schoeps B, Kabacaoglu D, Karpathaki AF, Ciecielski KJ, Kaya-Aksoy E, Ruess DA, Berninger A, Kowalska M, Stevanovic M, Wörmann SM, Wartmann T, Zhao Y, Halangk W, Voronina S, Tepikin A, Schlitter AM, Steiger K, Artati A, Adamski J, Aichler M, Walch A, Jastroch M, Hartleben G, Mantzoros CS, Weichert W, Schmid RM, Herzig S, Krüger A, Sainz B Jr, Lesina M, Algül H. Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice. Gastroenterology 2019;156:203-217.e20. [PMID: 30296435 DOI: 10.1053/j.gastro.2018.09.053] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
54 Wang K, Herr I. Machine-Learning-Based Bibliometric Analysis of Pancreatic Cancer Research Over the Past 25 Years. Front Oncol 2022;12:832385. [PMID: 35419289 DOI: 10.3389/fonc.2022.832385] [Reference Citation Analysis]
55 Nicolle R, Blum Y, Marisa L, Loncle C, Gayet O, Moutardier V, Turrini O, Giovannini M, Bian B, Bigonnet M, Rubis M, Elarouci N, Armenoult L, Ayadi M, Duconseil P, Gasmi M, Ouaissi M, Maignan A, Lomberk G, Boher JM, Ewald J, Bories E, Garnier J, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Grandval P, Barraud-Blanc M, Norguet E, Gilabert M, Delpero JR, Roques J, Calvo E, Guillaumond F, Vasseur S, Urrutia R, de Reyniès A, Dusetti N, Iovanna J. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Cell Rep 2017;21:2458-70. [PMID: 29186684 DOI: 10.1016/j.celrep.2017.11.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 19.0] [Reference Citation Analysis]
56 Iovanna J, Dusetti N. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road. Cancer Lett 2017;410:63-7. [PMID: 28947138 DOI: 10.1016/j.canlet.2017.09.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
57 Labriet A, De Mattia E, Cecchin E, Lévesque É, Jonker D, Couture F, Buonadonna A, D'Andrea M, Villeneuve L, Toffoli G, Guillemette C. Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. Front Pharmacol 2017;8:712. [PMID: 29066969 DOI: 10.3389/fphar.2017.00712] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
58 Gu XQ, Tang D, Wan P, Qin T, Yang TH, Wu J, Ji H, Liu JC, Xue F, Tang YJ, Xia Q. Multiple microRNAs regulate tacrolimus metabolism through CYP3A5. Pharmacol Res 2021;164:105382. [PMID: 33348024 DOI: 10.1016/j.phrs.2020.105382] [Reference Citation Analysis]
59 Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16:207-220. [PMID: 30718832 DOI: 10.1038/s41575-019-0109-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 176] [Article Influence: 68.0] [Reference Citation Analysis]
60 Ehlen L, Arndt J, Treue D, Bischoff P, Loch FN, Hahn EM, Kotsch K, Klauschen F, Beyer K, Margonis GA, Kreis ME, Kamphues C. Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. BMC Cancer. 2020;20:417. [PMID: 32404074 DOI: 10.1186/s12885-020-06929-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
61 Collisson EA, Maitra A. Pancreatic Cancer Genomics 2.0: Profiling Metastases. Cancer Cell 2017;31:309-10. [DOI: 10.1016/j.ccell.2017.02.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
62 Kuhlmann L, Cummins E, Samudio I, Kislinger T. Cell-surface proteomics for the identification of novel therapeutic targets in cancer. Expert Review of Proteomics 2018;15:259-75. [DOI: 10.1080/14789450.2018.1429924] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
63 Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. Presse Med 2019;48:e159-74. [PMID: 30879894 DOI: 10.1016/j.lpm.2019.02.025] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 14.0] [Reference Citation Analysis]
64 Kaur A, Riaz MS, Singh SK, Kishore U. Human Surfactant Protein D Suppresses Epithelial-to-Mesenchymal Transition in Pancreatic Cancer Cells by Downregulating TGF-β. Front Immunol 2018;9:1844. [PMID: 30158928 DOI: 10.3389/fimmu.2018.01844] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
65 Milan M, Diaferia GR, Natoli G. Tumor cell heterogeneity and its transcriptional bases in pancreatic cancer: a tale of two cell types and their many variants. EMBO J 2021;40:e107206. [PMID: 33844319 DOI: 10.15252/embj.2020107206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Ding LY, Hou YC, Kuo IY, Hsu TY, Tsai TC, Chang HW, Hsu WY, Tsao CC, Tian CC, Wang PS, Wang HC, Lee CT, Wang YC, Lin SH, Hughes MW, Chuang WJ, Lu PJ, Shan YS, Huang PH. Epigenetic silencing of AATK in acinar to ductal metaplasia in murine model of pancreatic cancer. Clin Epigenetics 2020;12:87. [PMID: 32552862 DOI: 10.1186/s13148-020-00878-6] [Reference Citation Analysis]
67 Wang Z, Hausmann S, Lyu R, Li TM, Lofgren SM, Flores NM, Fuentes ME, Caporicci M, Yang Z, Meiners MJ, Cheek MA, Howard SA, Zhang L, Elias JE, Kim MP, Maitra A, Wang H, Bassik MC, Keogh MC, Sage J, Gozani O, Mazur PK. SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. Cancer Cell 2020;37:834-849.e13. [PMID: 32442403 DOI: 10.1016/j.ccell.2020.04.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
68 Rodriguez-Antona C, Savieo JL, Lauschke VM, Sangkuhl K, Drögemöller BI, Wang D, van Schaik RHN, Gilep AA, Peter AP, Boone EC, Ramey BE, Klein TE, Whirl-Carrillo M, Pratt VM, Gaedigk A. PharmVar GeneFocus: CYP3A5. Clin Pharmacol Ther 2022. [PMID: 35202484 DOI: 10.1002/cpt.2563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
69 De Mattia E, Cecchin E, Roncato R, Toffoli G. Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine. Pharmacogenomics 2016;17:1547-71. [DOI: 10.2217/pgs-2016-0095] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
70 Bijlsma MF, Sadanandam A, Tan P, Vermeulen L. Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2017;14:333-42. [PMID: 28400627 DOI: 10.1038/nrgastro.2017.33] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 12.0] [Reference Citation Analysis]
71 Connor AA, Gallinger S. Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong? Expert Rev Gastroenterol Hepatol 2017;11:683-94. [PMID: 28460572 DOI: 10.1080/17474124.2017.1324296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
72 Yamaguchi T, Ikehara S, Akimoto Y, Nakanishi H, Kume M, Yamamoto K, Ohara O, Ikehara Y. TGF-β signaling promotes tube-structure-forming growth in pancreatic duct adenocarcinoma. Sci Rep 2019;9:11247. [PMID: 31375695 DOI: 10.1038/s41598-019-47101-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Invest. 2020;130:4704-4709. [PMID: 32749238 DOI: 10.1172/jci136760] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
74 Ingelman-sundberg M, Lauschke VM. Can CYP Inhibition Overcome Chemotherapy Resistance? Trends in Pharmacological Sciences 2020;41:503-6. [DOI: 10.1016/j.tips.2020.05.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
75 Satoh D, Abe S, Kobayashi K, Nakajima Y, Oshimura M, Kazuki Y. Human and mouse artificial chromosome technologies for studies of pharmacokinetics and toxicokinetics. Drug Metabolism and Pharmacokinetics 2018;33:17-30. [DOI: 10.1016/j.dmpk.2018.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
76 Lankes K, Hassan Z, Doffo MJ, Schneeweis C, Lier S, Öllinger R, Rad R, Krämer OH, Keller U, Saur D, Reichert M, Schneider G, Wirth M. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Mol Oncol 2020;14:3048-64. [PMID: 33099868 DOI: 10.1002/1878-0261.12835] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Oladimeji P, Cui H, Zhang C, Chen T. Regulation of PXR and CAR by protein-protein interaction and signaling crosstalk. Expert Opin Drug Metab Toxicol. 2016;12:997-1010. [PMID: 27295009 DOI: 10.1080/17425255.2016.1201069] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
78 [DOI: 10.1101/2020.08.25.267336] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. J Clin Oncol 2017;35:3330-7. [PMID: 28817370 DOI: 10.1200/JCO.2017.72.6463] [Cited by in Crossref: 124] [Cited by in F6Publishing: 67] [Article Influence: 24.8] [Reference Citation Analysis]
80 Weichert W, Sprick MR, Siveke JT. Still a hopeless case for personalized oncology? Pancreatic cancer revisited. Oncoscience 2019;6:285-6. [PMID: 30800713 DOI: 10.18632/oncoscience.464] [Reference Citation Analysis]
81 Kuhlmann L, Nadler WM, Kerner A, Hanke SA, Noll EM, Eisen C, Espinet E, Vogel V, Trumpp A, Sprick MR, Roesli CP. Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. Pancreas 2017;46:311-22. [DOI: 10.1097/mpa.0000000000000743] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
82 Wang P, Zhang C, Li W, Zhai B, Jiang X, Reddy S, Jiang H, Sun X. Identification of a robust functional subpathway signature for pancreatic ductal adenocarcinoma by comprehensive and integrated analyses. Cell Commun Signal 2020;18:34. [PMID: 32122386 DOI: 10.1186/s12964-020-0522-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Wright WC, Chenge J, Wang J, Girvan HM, Yang L, Chai SC, Huber AD, Wu J, Oladimeji PO, Munro AW, Chen T. Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5. J Med Chem 2020;63:1415-33. [PMID: 31965799 DOI: 10.1021/acs.jmedchem.9b02067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
84 Gutiérrez ML, Muñoz-Bellvís L, Orfao A. Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact. Cancers (Basel) 2021;13:4451. [PMID: 34503261 DOI: 10.3390/cancers13174451] [Reference Citation Analysis]
85 Lu Y, Xu D, Peng J, Luo Z, Chen C, Chen Y, Chen H, Zheng M, Yin P, Wang Z. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1. EBioMedicine 2019;44:403-18. [PMID: 31103629 DOI: 10.1016/j.ebiom.2019.05.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
86 Fan Z, Fan K, Deng S, Gong Y, Qian Y, Huang Q, Yang C, Cheng H, Jin K, Luo G, Liu C, Yu X. HNF-1a promotes pancreatic cancer growth and apoptosis resistance via its target gene PKLR. Acta Biochim Biophys Sin (Shanghai) 2020;52:241-50. [PMID: 32072180 DOI: 10.1093/abbs/gmz169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Seino T, Kawasaki S, Shimokawa M, Tamagawa H, Toshimitsu K, Fujii M, Ohta Y, Matano M, Nanki K, Kawasaki K, Takahashi S, Sugimoto S, Iwasaki E, Takagi J, Itoi T, Kitago M, Kitagawa Y, Kanai T, Sato T. Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. Cell Stem Cell. 2018;22:454-467.e6. [PMID: 29337182 DOI: 10.1016/j.stem.2017.12.009] [Cited by in Crossref: 201] [Cited by in F6Publishing: 199] [Article Influence: 50.3] [Reference Citation Analysis]
88 Pondugula SR, Pavek P, Mani S. Pregnane X Receptor and Cancer: Context-Specificity is Key. Nucl Receptor Res 2016;3:101198. [PMID: 27617265 DOI: 10.11131/2016/101198] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
89 Low RRJ, Lim WW, Nguyen PM, Lee B, Christie M, Burgess AW, Gibbs P, Grimmond SM, Hollande F, Putoczki TL. The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. Cancers (Basel) 2021;13:4979. [PMID: 34638463 DOI: 10.3390/cancers13194979] [Reference Citation Analysis]
90 Sereti E, Karagianellou T, Kotsoni I, Magouliotis D, Kamposioras K, Ulukaya E, Sakellaridis N, Zacharoulis D, Dimas K. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer? J Proteomics 2018;188:107-18. [PMID: 29398619 DOI: 10.1016/j.jprot.2018.01.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
91 Adehin A, Bolaji OO, Kennedy MA. Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population. Drug Metabolism and Pharmacokinetics 2017;32:189-91. [DOI: 10.1016/j.dmpk.2016.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
92 Bozza M, Green EW, Espinet E, De Roia A, Klein C, Vogel V, Offringa R, Williams JA, Sprick M, Harbottle RP. Novel Non-integrating DNA Nano-S/MAR Vectors Restore Gene Function in Isogenic Patient-Derived Pancreatic Tumor Models. Mol Ther Methods Clin Dev 2020;17:957-68. [PMID: 32420409 DOI: 10.1016/j.omtm.2020.04.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Giovannetti E, van der Borden CL, Frampton AE, Ali A, Firuzi O, Peters GJ. Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. Semin Cancer Biol 2017;44:43-59. [PMID: 28438662 DOI: 10.1016/j.semcancer.2017.04.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 10.0] [Reference Citation Analysis]
94 Andersen HB, Ialchina R, Pedersen SF, Czaplinska D. Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets. Cancer Metastasis Rev 2021. [PMID: 34855109 DOI: 10.1007/s10555-021-10004-4] [Reference Citation Analysis]
95 Xu Z, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R, Brors B, Gress T, Buchholz M, An J, Wei K, Peccerella T, Büchler MW, Hackert T, Neoptolemos JP. Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Front Cell Dev Biol 2021;9:743908. [PMID: 34805152 DOI: 10.3389/fcell.2021.743908] [Reference Citation Analysis]
96 Singhal M, Gengenbacher N, Abdul Pari AA, Kamiyama M, Hai L, Kuhn BJ, Kallenberg DM, Kulkarni SR, Camilli C, Preuß SF, Leuchs B, Mogler C, Espinet E, Besemfelder E, Heide D, Heikenwalder M, Sprick MR, Trumpp A, Krijgsveld J, Schlesner M, Hu J, Moss SE, Greenwood J, Augustin HG. Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasis. Sci Transl Med 2021;13:eabe6805. [PMID: 34516824 DOI: 10.1126/scitranslmed.abe6805] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Dantes Z, Yen HY, Pfarr N, Winter C, Steiger K, Muckenhuber A, Hennig A, Lange S, Engleitner T, Öllinger R, Maresch R, Orben F, Heid I, Kaissis G, Shi K, Topping G, Stögbauer F, Wirth M, Peschke K, Papargyriou A, Rezaee-Oghazi M, Feldmann K, Schäfer AP, Ranjan R, Lubeseder-Martellato C, Stange DE, Welsch T, Martignoni M, Ceyhan GO, Friess H, Herner A, Liotta L, Treiber M, von Figura G, Abdelhafez M, Klare P, Schlag C, Algül H, Siveke J, Braren R, Weirich G, Weichert W, Saur D, Rad R, Schmid RM, Schneider G, Reichert M. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. JCI Insight 2020;5:137809. [PMID: 32614802 DOI: 10.1172/jci.insight.137809] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
98 Knudsen ES, Balaji U, Mannakee B, Vail P, Eslinger C, Moxom C, Mansour J, Witkiewicz AK. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Gut 2018;67:508-20. [PMID: 28073890 DOI: 10.1136/gutjnl-2016-313133] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 14.3] [Reference Citation Analysis]
99 Huang X, Zhang G, Liang T. Subtyping for pancreatic cancer precision therapy. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.03.005] [Reference Citation Analysis]
100 Yan F, Cui Y, An Y, Ning J, Zhao X, Feng L, Huo X, Wang C, Lv C, Ma X, Tian X. A dual functional probe for assessing human CYP450 3A5 and 3A enzymes bioactivities. Future Med Chem 2019;11:2891-903. [PMID: 31702381 DOI: 10.4155/fmc-2019-0173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
101 Schlitter AM, Jesinghaus M, Jäger C, Konukiewitz B, Muckenhuber A, Demir IE, Bahra M, Denkert C, Friess H, Kloeppel G, Ceyhan GO, Weichert W. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. Eur J Cancer 2017;84:121-9. [PMID: 28802189 DOI: 10.1016/j.ejca.2017.06.034] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
102 Subramani R, Medel J, Flores K, Perry C, Galvez A, Sandoval M, Rivera S, Pedroza DA, Penner E, Chitti M, Lakshmanaswamy R. Hepatocyte nuclear factor 1 alpha influences pancreatic cancer growth and metastasis. Sci Rep 2020;10:20225. [PMID: 33214606 DOI: 10.1038/s41598-020-77287-5] [Reference Citation Analysis]
103 Roncato R, Angelini J, Pani A, Cecchin E, Sartore-Bianchi A, Siena S, De Mattia E, Scaglione F, Toffoli G. CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. Int J Mol Sci 2020;21:E6350. [PMID: 32883002 DOI: 10.3390/ijms21176350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
104 Lauschke VM, Nordling Å, Zhou Y, Fontalva S, Barragan I, Ingelman-sundberg M. CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma. Pharmacogenomics 2019;20:1085-92. [DOI: 10.2217/pgs-2019-0094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
105 Kloesch B, Ionasz V, Paliwal S, Hruschka N, Martinez de Villarreal J, Öllinger R, Mueller S, Dienes HP, Schindl M, Gruber ES, Stift J, Herndler-Brandstetter D, Lomberk GA, Seidler B, Saur D, Rad R, Urrutia RA, Real FX, Martinelli P. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer. Gut 2022;71:766-77. [PMID: 33846140 DOI: 10.1136/gutjnl-2020-321397] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
106 Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L, Wirth M, Dantes Z, Steiger K, Schunck K, Langston S, Lenhof HP, Coluccio A, Orben F, Slawska J, Scherger A, Saur D, Müller S, Rad R, Weichert W, Nilsson J, Reichert M, Schneider G, Keller U. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut 2020;69:1472-82. [PMID: 32001555 DOI: 10.1136/gutjnl-2018-317856] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 17.5] [Reference Citation Analysis]
107 Ai J, Wörmann SM, Görgülü K, Vallespinos M, Zagorac S, Alcala S, Wu N, Kabacaoglu D, Berninger A, Navarro D, Kaya-Aksoy E, Ruess DA, Ciecielski KJ, Kowalska M, Demir IE, Ceyhan GO, Heid I, Braren R, Riemann M, Schreiner S, Hofmann S, Kutschke M, Jastroch M, Slotta-Huspenina J, Muckenhuber A, Schlitter AM, Schmid RM, Steiger K, Diakopoulos KN, Lesina M, Sainz B Jr, Algül H. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Gastroenterology 2021;161:318-332.e9. [PMID: 33819482 DOI: 10.1053/j.gastro.2021.03.051] [Reference Citation Analysis]
108 Bian B, Bigonnet M, Gayet O, Loncle C, Maignan A, Gilabert M, Moutardier V, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Ouaissi M, Secq V, Poizat F, Nicolle R, Blum Y, Marisa L, Rubis M, Raoul JL, Bradner JE, Qi J, Lomberk G, Urrutia R, Saul A, Dusetti N, Iovanna J. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. EMBO Mol Med 2017;9:482-97. [PMID: 28275007 DOI: 10.15252/emmm.201606975] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
109 Feng Y, Wang C, Tian X, Huo X, Feng L, Sun C, Ge G, Yang L, Ning J, Ma X. In vitro phase I metabolism of gamabufotalin and arenobufagin: Reveal the effect of substituent group on metabolic stability. Fitoterapia 2017;121:38-45. [DOI: 10.1016/j.fitote.2017.06.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
110 Mohamed Abd-El-Halim Y, El Kaoutari A, Silvy F, Rubis M, Bigonnet M, Roques J, Cros J, Nicolle R, Iovanna J, Dusetti N, Mas E. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. EBioMedicine 2021;71:103541. [PMID: 34425307 DOI: 10.1016/j.ebiom.2021.103541] [Reference Citation Analysis]
111 Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature 2017;542:362-6. [PMID: 28178232 DOI: 10.1038/nature21064] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 13.6] [Reference Citation Analysis]
112 Giri B, Sethi V, Dudeja V, Banerjee S, Livingstone A, Saluja A. Genetics of pancreatic cyst-cancer progression: standing on the shoulders of giants. Curr Opin Gastroenterol 2017;33:404-10. [PMID: 28682795 DOI: 10.1097/MOG.0000000000000382] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Wang J, Buchman CD, Seetharaman J, Miller DJ, Huber AD, Wu J, Chai SC, Garcia-Maldonado E, Wright WC, Chenge J, Chen T. Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5. J Am Chem Soc 2021;143:18467-80. [PMID: 34648292 DOI: 10.1021/jacs.1c07066] [Reference Citation Analysis]
114 Wang Z, Dong J, Zhao Q, Ying Y, Zhang L, Zou J, Zhao S, Wang J, Zhao Y, Jiang S. Gold nanoparticle‑mediated delivery of paclitaxel and nucleic acids for cancer therapy (Review). Mol Med Rep 2020;22:4475-84. [PMID: 33173972 DOI: 10.3892/mmr.2020.11580] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
115 Berger AK, Singh HM, Werft W, Muckenhuber A, Sprick MR, Trumpp A, Weichert W, Jäger D, Springfeld C. High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study. Pancreatology 2017;17:629-34. [DOI: 10.1016/j.pan.2017.04.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]